Underperforming against its competitors, Centene Corporation (CNC) recently instated its first president overseeing Individual Coverage Health Reimbursement Arrangements. Despite notable weakness in its stock performance and a touch of 52-week low of $62.99, financials have shown solid strength hinting a potential profitable value stock for future investors. Healthy insider trading activity, accompanied by growth in memberships, premium and service sales, has poised CNC as a moderate buy for brokerages. The company confidently reaffirmed its 2024 earnings guidance and announced to host an investor day on December 12, 2024. On the negative note, Medicaid enrollment concerns alongside market shifts have called into question the sheer profitability of the CNC stock. In a noteworthy development, Health Net, a Centene subsidiary, is the only health plan in the US to have received 'Health Equity Accreditation Plus' across all business lines for 2024. Furthermore, Centene was named among Fortune's top 100 large workplaces for women in 2024 and Best Workplaces in Health Care 2024.
Centene Corporation CNC News Analytics from Sat, 27 Apr 2024 07:00:00 GMT to Sat, 11 Jan 2025 09:22:47 GMT -
Rating 2
- Innovation 6
- Information 7
- Rumor -1
